GlaxoSmithKline Plc's breast cancer vaccine was recommended for approval by European drug regulators on Thursday but they warned of potential liver toxicity, according to a report.

The treatment for advanced or metastatic breast cancer has a positive benefit-risk balance, according to the European Medicine Agency. It submitted the vaccine, named Tykerb or Tyverb, for examination due to some hepatotoxicity effects.

Recommendations made by the agency to introduce drugs to the market are normally supported by the European Commission within a couple of months.

Glaxo is introducing the breast cancer treatment as a pill and has significant expectations from the company. The drug Tykerb works within cells instead of attacking them from the outside.

Shares of GlaxoSmithKline Plc. were 0.58 cents down by $44.35 at 3:29 p.m. in the New York Stock Exchange.

American Depositary Receipts of GlaxoSmithKline Plc fell 1.1 percent, or 49 cents to close at $44.12 on the New York Stock Exchange.

Glaxosmithkline Breast cancer